Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584028 | 0.81 | CYP2C19 (0.47) | CYP2C19HIF1AHDAC3HDAC4HDAC1 | |
| SCHEMBL7899580 | 0.81 | CYP2C19 (0.47) | CYP2C19HIF1AHDAC3HDAC4HDAC1 | |
| SCHEMBL5570579 | 0.81 | CYP2C19 (0.47) | CYP2C19HIF1AHDAC3HDAC4HDAC1 | |
| Ammonia Solution, Strong SCHEMBL3396016 | 0.79 | CYP2C19 (0.45) | CYP2C19HIF1ALMNAHTTL3MBTL1 | |
| SCHEMBL14723764 | 0.79 | CYP2C19 (0.45) | CYP2C19HIF1AHDAC3HDAC4HDAC1 | |
| SCHEMBL13946510 | 0.78 | MAPT (0.55) | CYP2C19HIF1ALMNAHTTL3MBTL1 | |
| SCHEMBL3837958 | 0.78 | MAPT (0.55) | CYP2C19HIF1ALMNAHTTL3MBTL1 | |
| SCHEMBL13946506 | 0.78 | MAPT (0.55) | CYP2C19HIF1ALMNAHTTL3MBTL1 | |
| SCHEMBL10730469 | 0.77 | GLS (0.49) | CYP2C19HIF1AHDAC3HDAC4HDAC1 | |
| SCHEMBL8910393 | 0.77 | KMT2A (0.48) | CYP2C19HIF1AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-01 | — | — | US | disclosed |
| US-8211928-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885HIF1A 3448/4885HDAC3 2171/4885 |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885HIF1A 3448/4885HDAC3 2171/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885HIF1A 3448/4885HDAC3 2171/4885 |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885HIF1A 3448/4885HDAC3 2171/4885 |
| US-20120277266-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4311/4885HIF1A 3448/4885HDAC3 2171/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP2C19 4378/4885HIF1A 3245/4885HDAC3 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.